RecruitingPhase 2interventionalRules rewrite

Phase 2: testing EVO756, Dose 1 for Migraine

Q: Is NCT07616128 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07616128?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07616128?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

This study will measure the how well it works and safety of EVO756 against dummy treatment (placebo) in adults with migraine.

Official registry: https://clinicaltrials.gov/study/NCT07616128 · Evommune, Inc. · enrollment listed as 330

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are EVO756, Dose 1, EVO756, Dose 2, or Placebo. The registry lists allocation as randomized. This study will measure the how well it works and safety of EVO756 against dummy treatment (placebo) in adults with migraine.

They plan to enroll about 330 people at 45 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults

Interventions: EVO756, Dose 1, EVO756, Dose 2, Placebo

Primary outcome (registry wording): Mean change from baseline in the number of monthly migraine days (MMD)

Who it is for (from inclusion criteria)

Ages 18 Years to 64 Years
Adults aged 18 to \<65 years
Migraine with or without aura, per ICHD-3 criteria
History of failure with prior preventive migraine treatments
Not currently using migraine preventive therapy

Who the registry excludes

Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
Use of certain medications
Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities

Public study contact (from the registry)

Nichole Baio

(650) 319-4553

nichole.baio@evommune.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

45 listed

Trialsphere Corp — Chandler, Arizona (recruiting)
Buena Park Research Center — Buena Park, California (active_not_recruiting)
Neuro Pain Research Center — Fresno, California (recruiting)
Salma Health La Jolla — La Jolla, California (recruiting)
CA Medical Clinic for Headache — Los Angeles, California (recruiting)
Diablo Clinical Research dba Flourish Research — Walnut Creek, California (recruiting)
Denver Neurological Clinic — Denver, Colorado (recruiting)
Hasbani Neurology — New Haven, Connecticut (recruiting)
New England Institute for Neurology and Headache — Stamford, Connecticut (recruiting)
Clinical Neuroscience Solutions, Inc. — Jacksonville, Florida (active_not_recruiting)
Apple Medical Research Group, Inc — Miami, Florida (recruiting)
Blessed Healthcase & Research — Miami, Florida (recruiting)

+ 8 sites outside the US on the same record

Related recruiting trials in this snapshot

RecruitingPhase 3Birmingham, Alabama

Phase 3: testing Rimegepant/BHV3000 for Pediatric Migraine

This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.

NCT04649242 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3Scottsdale, Arizona

Phase 3: testing Rimegepant (PF-07899801) for Acute Treatment of Migraine

This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).

NCT04743141 · Official ClinicalTrials.gov record · Pfizer

RecruitingPhase 3New Haven, Connecticut

Phase 3: testing Eptinezumab for Chronic Migraine in Children

To find out if eptinezumab is better than dummy treatment (placebo) (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

NCT04965675 · Official ClinicalTrials.gov record · H. Lundbeck A/S

FAQ about this NCT record

Is NCT07616128 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07616128?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07616128?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary